In new research, Hao Yan and his colleagues at Arizona State University's Biodesign Institute describe a pair of tweezers shrunk down to an astonishingly tiny scale. When the jaws of these tools are in the open position, the distance between the two arms is about 16 nanometers.
Early-stage MitrAssist whizzed by it's hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company's mitral valve implant. MitrAssist, a spin-out of Tredline Group's accelerator program, is developing what it calls a "valve-on-valve" approach to treat mitral regurgitation for patients too elderly or unstable for an invasive open-heart operation.
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests. The funding, raised among 20 unnamed investors, will support Iguana's interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
One of the greatest pleasures I have as FDA commissioner is the opportunity to meet with so many who are making a real difference in the world of health care, including researchers, doctors, drug industry leaders, foundations, and advocates for patients and families, including most recently the Alexandria Summit for Oncology.
Guided Therapeutics Continues to Await Update from FDA on Its PMA Application for LuViva® Advanced Cervical ScanJuly 3, 2013 8:06 am | News | Comments
Guided Therapeutics commented on the status of its Pre-market Approval application for the LuViva Advanced Cervical Scan. While the Company requested a phone meeting with the FDA after the passing of their 180 day internal guidance and did speak with the agency, the company was informed that LuViva remains under FDA review.
Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells. Founded in 2010, the Seattle, Wash.-based Blaze Biosciences has roped in about $8.1 million since opening the round in June.
Under fire for being too lenient with medical device approvals, European regulators proposed an update to current CE Mark review and approval practices. Specifically, the European Commission's proposed changes address the relative ease with which companies can secure CE Mark approval by "shopping" for an agency in a specific country that will most quickly green-light a new device.
Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa, today announced that its wireless subretinal implant technology, the Alpha IMS, has received CE Mark. Retina Implant's technology, which has been in clinical trials across the world since 2005, is designed to restore useful vision in patients blinded by the degenerative eye condition retinitis pigmentosa.
Omnetics’ micro-circular and nano-circular connectors include custom cable designs for high quality signal and EMI protection. Designers find a significant advantage in size reduction and cable flexibility when using the Omnetics miniaturized circular connectors and cables.
New PEM Type SFN spinning flare nuts are designed to rotate freely when permanently captivated in thin metal sheets for quick attachment to mating hardware and reduced need for loose fasteners such as flange nuts.
ArthroCare (NSDQ:ARTC) said it closed its $45 million acquisition of ENTrigue Surgical and bought a nearly 20% stake in Israeli medical device company Ortho-Space. The deal price for ENTrigue, which makes a device to treat chronic sinusitis, includes "contingent consideration" pegged to sales growth milestones, according to a press release.
Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014. As of about 2:45 p.m. DaVita Inc. (NYSE:DVA) was down 5.8% to $114.16 and Fresenius (NYSE:FMS) was down 9.8% to $32.03.
North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.
Some 55 U.S. hospitals agreed to pay a total of $34 million to settle U.S. Justice Dept. charges that they overcharged Medicare for Medtronic's (NYSE:MDT)'s kyphoplasty spine procedure, acquired in the $3.9 billion buyout of Kyphon in 2007, the Justice Dept. said today.
Minnesota medical device giant Medtronic (NYSE:MDT) confirmed today that it recalled certain of its already-troubled Infuse spinal fusion surgery kits after learning of possible contamination in sponges manufactured by Integra Lifesciences.